

Correction: In situ induction of dendritic cell–based T cell tolerance in humanized mice and nonhuman primates

Kyeong Cheon Jung, Chung-Gyu Park, Yoon Kyung Jeon, Hyo Jin Park, Young Larn Ban, Hye Sook Min, Eun Ji Kim, Ju Hyun Kim, Byung Hyun Kang, Seung Pyo Park, Youngmee Bae, Il-Hee Yoon, Yong-Hee Kim, Jae-Il Lee, Jung-Sik Kim, Jun-Seop Shin, Jaeseok Yang, Sung Joo Kim, Emily Rostlund, William A. Muller, and Seong Hoe Park

Vol. 208, No. 12, November 21, 2011. Pages 2477–2488.

The authors regret that a measurement was incorrect and that the source of the 5C8 clone was left out of the original publication. The corrected sentence in the Results section MD-3 efficiently induces antigen-specific T cell tolerance in nonhuman primates appears below.

“However, long-term graft survival was finally achieved with a combination treatment of low-dose rapamycin (trough level 6–12 ng/ml) and mouse–human IgG1 chimeric anti–human CD154 blocking antibody (5C8 clone derivative; National Institutes of Health Nonhuman Primate Reagent Resource), as well as MD-3.”

In addition, the following sentence has been added to the second paragraph of the Acknowledgements section.

“The anti-CD154 antibody used in these experiments was provided by the National Institutes of Health Nonhuman Primate Reagent Resource (National Institute of Allergy and Infectious Diseases contract HHSN 2722001300031C).”

The HTML and PDF versions of this paper have been edited to reflect these corrections.